Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Provided By PR Newswire
Last update: Jan 22, 2025
USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Jan. 22, 2025 /PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25 in San Francisco. This year's event is particularly critical as researchers highlight the alarming rise in cancer rates among people under 50, with gastrointestinal cancers leading the increase. Colorectal and pancreatic cancers, two of the top three deadliest cancer types, remain significant concerns as pancreatic cancer mortality continues to climb. Among the innovators presenting at the symposium are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Agenus Inc. (NASDAQ: AGEN), Guardant Health, Inc. (NASDAQ: GH), Xilio Therapeutics, Inc. (NASDAQ: XLO), and RenovoRx, Inc. (NASDAQ: RNXT).
Read more at prnewswire.com39.32
-0.85 (-2.12%)
1.06
-0.25 (-19.08%)
NASDAQ:RNXT (3/7/2025, 8:00:02 PM)
0.957
-0.02 (-1.83%)
2.35
0 (0%)
0.9085
-0.02 (-2.59%)
0.6888
-0.05 (-6.29%)
Find more stocks in the Stock Screener
